Potential biomarkers in gallbladder cancer: Present status and future directions

Biomarkers

Volumn 18, Issue 1, 2013, Pages 1-9

  Srivastava, Kshitij ^a   Srivastava, Anvesha ^b   Mittal, Balraj ^c  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

^c SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Biomarker; Cancer; Expression; Gallbladder; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

CANCER GENETICS; CANCER SCREENING; CANCER SUSCEPTIBILITY; DISEASE MARKER; GALLBLADDER CARCINOMA; GENE EXPRESSION; HUMAN; REVIEW; TUMOR MICROENVIRONMENT;

AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; GALLBLADDER; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872573153     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.717105     Document Type: Review

References (92)

1. Alvarez H, Corvalan A, Roa JC, Argani P, Murillo F, Edwards J, Beaty R, Feldmann G, Hong SM, Mullendore M, Roa I, Ibañez L, Pimentel F, Diaz A, Riggins GJ, Maitra A. (2008). Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer. Clin Cancer Res 14:2631-2638.
2. Aswad B, Constantinou M, Isanitti D, Nadeem A, King T, Wesep RV, Rathore R, Howard S. (2002). C-kit is a potential therapeutic target for biliary carcinomas [abstract]. Proc Am Soc Clin Oncol 21:13.
3. Bartel DP. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
4. Braconi C, Huang N, Patel T. (2010). MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51:881-890.
5. Brinkman BM. (2004). Splice variants as cancer biomarkers. Clin Biochem 37:584-594.
6. Cao L, Duchrow M, Windhövel U, Kujath P, Bruch HP, Broll R. (1998). Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur J Cancer 34:1612-1617.
7. Cha PC, Zembutsu H, Takahashi A, Kubo M, Kamatani N, Nakamura Y. (2012). A genome-wide association study identifies SNP in DCC is associated with gallbladder cancer in the Japanese population. J Hum Genet 57:235-237.
8. Chaube A, Tewari M, Singh U, Shukla HS. (2006). CA 125: A potential tumor marker for gallbladder cancer. J Surg Oncol 93:665-669.
9. Desmetz C, Mange A, Maudelonde T, Solassol J. (2011). Autoantibody signatures: Progress and perspectives for early cancer detection. J Cell Mol Med 15:2013-2024.
10. Enjoji M, Nakashima M, Nishi H, Choi I, Oimomi H, Sugimoto R, Kotoh K, Taguchi K, Nakamuta M, Nawata H, Watanabe T. (2002). The tumor-associated antigen, RCAS1, can be expressed in immunemediated diseases as well as in carcinomas of biliary tract. J Hepatol 36:786-792.
11. Enjoji M, Yamaguchi K, Nakamuta M, Nakashima M, Kotoh K, Tanaka M, Nawata H, Watanabe T. (2004). Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig Liver Dis 36:622-627.
12. Furuse J. (2010). Targeted therapy for biliary-tract cancer. Lancet Oncol 11:5-6.
13. Gabbi C, Kim HJ, Barros R, Korach-Andrè M, Warner M, Gustafsson JA. (2010). Estrogen-dependent gallbladder carcinogenesis in LXRbeta-/- female mice. Proc Natl Acad Sci USA 107:14763-14768.
14. García P, Manterola C, Araya JC, Villaseca M, Guzmán P, Sanhueza A, Thomas M, Alvarez H, Roa JC. (2009). Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog 48:79-89.
15. Giatromanolaki A, Sivridis E, Koukourakis MI, Polychronidis A, Simopoulos C. (2002). Prognostic role of angiogenesis in operable carcinoma of the gallbladder. Am J Clin Oncol 25:38-41.
16. Gowda GA. (2010). Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomark Med 4:299-314.
17. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Shulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R, Wistuba II, Varma R, Hawthorne L, Geradts J, Argani P, Maitra A. (2003). Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163:217-229.
18. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IeM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, De Marzo AM, Terracciano L, Torbenson M, Meeker AK. (2011). Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608-1615.
19. Hemminki K, Li X. (2003). Familial liver and gall bladder cancer: A nationwide epidemiological study from Sweden. Gut 52:592-596.
20. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. (2003). Identifying biological themes within lists of genes with EASE. Genome Biol 4:R70.
21. House MG, Wistuba II, Argani P, Guo M, Schulick RD, Hruban RH, Herman JG, Maitra A. (2003). Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol 10:882-889.
22. Jackson HH, Glasgow RE, Mulvihill SJ, Cannon-Albright LA. (2007). Familial risk in gallbladder cancer. J Am Coll Surg 205:S38-S38.
23. Jayalakshmi K, Sonkar K, Behari A, Kapoor VK, Sinha N. (2010). Lipid profiling of cancerous and benign gallbladder tissues by (1)H NMR spectroscopy. NMR Biomed. Jayalakshmi K, Sonkar K, Behari A, Kapoor VK, Sinha N. (2009). Solid state (13)C NMR analysis of human gallstones from cancer and benign gall bladder diseases. Solid State Nucl Magn Reson 36:60-65.
24. Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, Wistuba II, Minna JD, Mangelsdorf DJ. (2010). Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med 7:e1000378.
25. Karrila S, Lee JH, Tucker-Kellogg G. (2011). A comparison of methods for data-driven cancer outlier discovery, and an application scheme to semisupervised predictive biomarker discovery. Cancer Inform 10:109-120.
26. Kawahara R, Odo M, Kinoshita H, Shirouzu K, Aoyagi S. (2007). Analysis of hTERT mRNA expression in biliary tract and pancreatic cancer. J Hepatobiliary Pancreat Surg 14:189-193.
27. Kee SK, Lee JY, Kim MJ, Lee SM, Jung YW, Kim YJ, Park JY, Bae HI, Hong HS, Yun YK, Kim SG, Kim DS. (2007). Hypermethylation of the Ras association domain family 1A (RASSF1A) gene in gallbladder cancer. Mol Cells 24:364-371.
28. Kiguchi K, Carbajal S, Chan K, Beltrán L, Ruffino L, Shen J, Matsumoto T, Yoshimi N, DiGiovanni J. (2001). Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61:6971-6976.
29. Kiguchi K, DiGiovanni J. (2008). Role of growth factor signaling pathways. In: Thomas CR, Fuller CD, eds. Biliary Tract and Gallbladder Cancer: Diagnosis & Therapy. New York, NY: Demos Medical, 19-36.
30. Kim JH, Kim HN, Lee KT, Lee JK, Choi SH, Paik SW, Rhee JC, Lowe AW. (2008). Gene expression profiles in gallbladder cancer: The close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis. Tumour Biol 29:41-49.
31. Kohya N, Miyazaki K, Matsukura S, Yakushiji H, Kitajima Y, Kitahara K, Fukuhara M, Nakabeppu Y, Sekiguchi M. (2002). Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 9:371-379.
32. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A. (2004). Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 101:1609-1615.
33. Koslinski P, Bujak R, Daghir E, Markuszewski MJ. (2011). Metabolic profiling of pteridines for determination of potential biomarkers in cancer diseases. Electrophoresis 32:2044-2054.
34. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, Argani P, Goggins MG, Maitra A, Pandey A. (2004). A proteomic analysis of human bile. Mol Cell Proteomics 3:715-728.
35. Langner C, Lemmerer M, Kornprat P. (2004). Analysis of KIT (CD117) expression in gallbladder carcinomas by tissue microarray. Eur J Surg Oncol 30:847-850.
36. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F. (2001). Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51:349-364.
37. Lee YM, Lee JY, Kim MJ, Bae HI, Park JY, Kim SG, Kim DS. (2006). Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci 97:1205-1210.
38. Li XX, Wang J, Wang HL, Wang W, Yin XB, Li QW, Chen YY, Yi J. (2012). Characterization of cancer stem-like cells derived from a side population of a human gallbladder carcinoma cell line, SGC-996. Biochem Biophys Res Commun 419:728-734.
39. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. (2000). Environmental and heritable factors in the causation of cancerYanalyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78-85.
40. Ma HB, Hu HT, Di ZL, Wang ZR, Shi JS, Wang XJ, Li Y. (2005). Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma. World J Gastroenterol 11:744-747.
41. Man Y. (2011). Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. Life Sci 89:65-71.
42. Marziliano N, Grasso M, Pilotto A, Porcu E, Tagliani M, Disabella E, Diegoli M, Pasotti M, Favalli V, Serio A, Gambarin F, Tavazzi L, Klersy C, Arbustini E. (2009). Transcriptomic and proteomic analysis in the cardiovascular setting: Unravelling the disease? J Cardiovasc Med (Hagerstown) 10:433-442.
43. Matarraz S, González-González M, Jara M, Orfao A, Fuentes M. (2011). New technologies in cancer. Protein microarrays for biomarker discovery. Clin Transl Oncol 13:156-161.
44. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics. (2006). REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235.
45. Miller G, Socci ND, Dhall D, D'Angelica M, DeMatteo RP, Allen PJ, Singh B, Fong Y, Blumgart LH, Klimstra DS, Jarnagin WR. (2009). Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res 28:62.
46. Mironov AA, Fickett JW, Gelfand MS. (1999). Frequent alternative splicing of human genes. Genome Res 9:1288-1293.
47. Misra S, Chaturvedi A, Misra NC, Sharma ID. (2003). Carcinoma of the gallbladder. Lancet Oncol 4:167-176.
48. Miura N, Hasegawa J, Shiota G. (2008). Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin Med Oncol 2:511-527.
49. Mou Y, Xing R, Liu C. (2012). Diagnosis of gallbladder cancer using matrix-assisted laser desorption/ionization time-of-flight profiling. Am J Med Sci 343:119-123.
50. Murakawa K, Tada M, Takada M, Tamoto E, Shindoh G, Teramoto K, Matsunaga A, Komuro K, Kanai M, Kawakami A, Fujiwara Y, Kobayashi N, Shirata K, Nishimura N, Okushiba S, Kondo S, Hamada J, Katoh H, Yoshiki T, Moriuchi T. (2004). Prediction of lymph node metastasis and perineural invasion of biliary tract cancer by selected features from cDNA array data. J Surg Res 122:184-194.
51. Nagasaki K, Miki Y. (2008). Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. Breast Cancer 15:117-120.
52. North JH Jr, Pack MS, Hong C, Rivera DE. (1998). Prognostic factors for adenocarcinoma of the gallbladder: An analysis of 162 cases. Am Surg 64:437-440.
53. Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K. (2008). Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncol Rep 20:279-286.
54. Okada K, Kijima H, Imaizumi T, Hirabayashi K, Matsuyama M, Yazawa N, Oida Y, Dowaki S, Tobita K, Ohtani Y, Tanaka M, Inokuchi S, Makuuchi H. (2009). Stromal laminin-5gamma2 chain expression is associated with the wall-invasion pattern of gallbladder adenocarcinoma. Biomed Res 30:53-62.
55. Paget S. (1889). The distribution of secondary growths in cancer of the breast. Lancet 133:571-573.
56. Pang Y, Young CY, Yuan H. (2010). MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42:363-369.
57. Park JY, Park BK, Ko JS, Bang S, Song SY, Chung JB. (2006). Bile acid analysis in biliary tract cancer. Yonsei Med J 47:817-825.
58. Piehler JM, Crichlow RW. (1977). Primary carcinoma of the gallbladder. Arch Surg 112:26-30.
59. Priya R, Pandey M, Shukla VK. (2008). Biomarkers in carcinoma of the gallbladder. Expert Opin Med Diagn 2:511-526.
60. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR. (2010). Molecular biomarker analyses using circulating tumor cells. PLoS ONE 5:e12517.
61. Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. (2001). Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 193:380-383.
62. Rana S, Dutta U, Kochhar R, Rana SV, Gupta R, Pal R, Jain K, Srinivasan R, Nagi B, Nain CK, Singh K. (2012). Evaluation of CA 242 as a tumor marker in gallbladder cancer. J Gastrointest Cancer 43:267-271.
63. Ribatti D, Vacca A. (2008). The role of microenvironment in tumor angiogenesis. Genes Nutr 3:29-34.
64. Riquelme E, Tang M, Baez S, Diaz A, Pruyas M, Wistuba II, Corvalan A. (2007). Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett 250:100-106.
65. Roa I, Araya JC, Villaseca M, De Aretxabala X, Riedemann P, Endoh K, Roa J. (1996). Preneoplastic lesions and gallbladder cancer: An estimate of the period required for progression. Gastroenterology 111:232-236.
66. Robert J, Vekris A, Pourquier P, Bonnet J. (2004). Predicting drug response based on gene expression. Crit Rev Oncol Hematol 51:205-227.
67. Saika K, Matsuda T. (2010). Comparison of time trends in gallbladder cancer mortality (1990-2006) between countries based using the WHO mortality database. Jpn J Clin Oncol 40:374-375.
68. Sato K, Kitajima Y, Kohya N, Koga Y, Ohtaka K, Miyazaki K. (2007). CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. Anticancer Res 27:865-872.
69. Sato K, Kitajima Y, Miyoshi A, Koga Y, Miyazaki K. (2006). Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. Int J Oncol 29:429-435.
70. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425-436.
71. Schwarzenbach H, Hoon DS, Pantel K. (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426-437.
72. Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R. (2010). CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther 10:1182-1190.
73. Shi CJ, Gao J, Wang M, Wang X, Tian R, Zhu F, Shen M, Qin RY. (2011). CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. World J Gastroenterol 17:2965-2971.
74. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S. (2008). Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135:1358-1368, 1368.e1.
75. Shukla VK, Gurubachan, Sharma D, Dixit VK, Usha. (2006). Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. Trop Gastroenterol 27:160-165.
76. Somashekar BS, Ijare OB, Gowda GA. (2007). Analysis of bile and gallbladder tissue by NMR: A route for diagnosis of gallbladder cancer. Proc Intl Soc Mag Reson Med 15:127.
77. Srivastava K, Srivastava A, Sharma KL, Mittal B. (2011). Candidate gene studies in gallbladder cancer: A systematic review and metaanalysis. Mutat Res 728:67-79.
78. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. (2011). Circulating tumor cells: Advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 137:1151-1173.
79. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH, Argani P. (2004). Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35:357-366.
80. Takahashi T, Shivapurkar N, Riquelme E, Shigematsu H, Reddy J, Suzuki M, Miyajima K, Zhou X, Bekele BN, Gazdar AF, Wistuba II. (2004). Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res 10:6126-6133.
81. Tan Y, Ma SY, Wang FQ, Meng HP, Mei C, Liu A, Wu HR. (2011). Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncol Rep 26:853-859.
82. Tan Y, Meng HP, Wang FQ, Cheng ZN, Wu Q, Wu HR. (2010). [Comparative proteomic analysis of human gallbladder carcinoma]. Zhonghua Zhong Liu Za Zhi 32:29-32.
83. Tanaka S, Takahashi R, Kitadai Y, Sumii M, Yoshihara M, Haruma K, Chayama K. (2003). Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64:266-274.
84. Tian Y, Ding RY, Zhi YH, Guo RX, Wu SD. (2006). Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 12:415-419.
85. Uchida N, Tsutsui K, Ezaki T, Fukuma H, Kobara H, Kamata H, Aritomo Y, Masaki T, Watanabe S, Kobayashi S, Nakatsu T, Nakano H, Kuriyama S. (2003). Combination of assay of human telomerase reverse transcriptase mRNA and cytology using bile obtained by endoscopic transpapillary catheterization into the gallbladder for diagnosis of gallbladder carcinoma. Am J Gastroenterol 98:2415-2419.
86. Ueki T, Hsing AW, Gao YT, Wang BS, Shen MC, Cheng J, Deng J, Fraumeni JF Jr, Rashid A. (2004). Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China. Clin Cancer Res 10:1717-1725.
87. Wang JW, Peng SY, Li JT, Wang Y, Zhang ZP, Cheng Y, Cheng DQ, Weng WH, Wu XS, Fei XZ, Quan ZW, Li JY, Li SG, Liu YB. (2009). Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett 281:71-81.
88. Washiro M, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Sugimoto T, Seki N, Miyazaki M. (2008). Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: A potential chemotherapeutic target. J Cancer Res Clin Oncol 134:793-801.
89. Wen H, Yoo SS, Kang J, Kim HG, Park JS, Jeong S, Lee JI, Kwon HN, Kang S, Lee DH, Park S. (2010). A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol 52:228-233.
90. Wistuba II, Albores-Saavedra J. (1999). Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 6:237-244.
91. Wistuba II, Gazdar AF. (2004). Gallbladder cancer: Lessons from a rare tumour. Nat Rev Cancer 4:695-706.
92. Zhu AX, Hezel AF. (2011). Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities. Hepatology 53:695-704.